Leukocyte Patents (Class 424/93.71)
-
Publication number: 20150118207Abstract: The present invention relates to a method for producing natural killer cells (hereinafter, referred to as “NK cells”), NK cells produced thereby, and a composition for treating cancers and infectious diseases containing the same. The present invention provides a method for producing NK cells, which maintain high cytotoxicity and cell viability to exhibit high therapeutic effects against cancers and infectious diseases and can be cultured ex vivo at high efficiency and high concentration. In addition, a culture method which maintains cell concentration at a constant level is used for the production of NK cells, and thus the overgrowth of the cells can be prevented so that the cells can be maintained at an optimal state. Particularly, even when the cells are thawed after freezing, the function of the cells is not impaired, and the NK cells can maintain high cell viability and cytotoxicity.Type: ApplicationFiled: December 18, 2012Publication date: April 30, 2015Applicants: Mogam Biotechnology Institute, Green Cross LabcellInventors: Bokyung Min, Hana Choi, Okjae Lim, Jung Hyun Her, Sangmi Kang, Eun-Kyoung Lee, Hyejin Chung, Yu Kyeong Hwang
-
Publication number: 20150110760Abstract: The invention is directed to T cells and other cells that express chimeric NK-p30 receptors (“chimeric NKp30 T cells”), methods of making and using chimeric NKp30 T cells, and methods of using these chimeric NKp30 T cells, isolated populations thereof, and compositions comprising the same. In another aspect, said chimeric NKp30 T cells are further designed to express a functional non-TCR receptor. The disclosure also pertains to methods of making said chimeric NKp30 T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said chimeric NKp30 T cells, populations thereof, or compositions comprising the same.Type: ApplicationFiled: August 31, 2012Publication date: April 23, 2015Applicant: Trustees of Dartmouth CollegeInventors: Tong Zhang, Charles L. Sentman
-
Publication number: 20150110761Abstract: The present disclosure relates generally to the manufacture of regulatory T cells (Tregs) for use in immunotherapy. In particular, the present disclosure relates to robust approaches for the expansion of alloantigen-reactive Tregs ex vivo. Alloantigen-reactive Tregs produced in this way are suitable for the induction and/or maintenance of immunologic tolerance in recipients of allogeneic transplants.Type: ApplicationFiled: March 1, 2013Publication date: April 23, 2015Inventors: Qizhi Tang, Jeffrey A. Bluestone
-
Publication number: 20150110737Abstract: The invention is directed to a method of preparing B-cells that produce interleukin-10 (IL-10), or IL-10 per se, which comprises contacting one or more B-cells ex vivo with an isolated interleukin-35 (IL-35) protein, and culturing the one or more B-cells under conditions to provide one or more B-cells that produce IL-10. The invention also is directed to a method of suppressing the proliferation of lymphocytes in vitro or in vivo by contacting lymphocytes with an isolated IL-35 protein. The invention further is directed to a method of suppressing autoimmunity in a mammal by administering to the mammal an IL-35 protein or IL-10-producing B-cells.Type: ApplicationFiled: April 11, 2013Publication date: April 23, 2015Inventors: Charles Emeka Egwuagu, Ren-Xi Wang, Cheng-rong Yu
-
Publication number: 20150110738Abstract: The present invention is directed to generating suppressor cells by treating naive T cells with a suppressor-inducing composition such as anti-CD3, anti-CD28, IL-2, TGF-?, or some combination thereof. Such suppressor cells are administered to patients to prevent or treat immune disorders and are allogeneic to the patient.Type: ApplicationFiled: May 2, 2013Publication date: April 23, 2015Inventor: David Horwitz
-
Publication number: 20150110762Abstract: The present disclosure is in the field of genome engineering, particularly targeted modification of the genome of a cell.Type: ApplicationFiled: October 16, 2014Publication date: April 23, 2015Inventors: Michael C. Holmes, Jianbin Wang
-
Patent number: 9011867Abstract: The present invention relates to the use of a peptide comprising or essentially consisting of a sequence motif as shown in SEQ ID NO: 1 for the preparation of a medicament for the treatment of Monoclonal Gammopathy of Undetermined Significance (MGUS) or of Smoldering Multiple Myeloma (SMM). Moreover, the present invention relates to the use of an activated T-cell specifically recognizing the peptide of the present invention or an antigen presenting cell which specifically presents a peptide epitope of the present invention for the preparation of a medicament for the treatment of Monoclonal Gammopathy of Undetermined Significance (MGUS) or of Smoldering Multiple Myeloma (SMM). The present invention also relates to a method for the ex vivo manufacture of an activated T-cell of the present invention comprising the steps of: a) obtaining T-cells from a sample of a subject suffering from MGUS or SMM, b) contacting said T-cells with a peptide of the present invention, and c) collecting the activated T-cells.Type: GrantFiled: February 1, 2010Date of Patent: April 21, 2015Assignee: Ruprecht-Karls-Universitat HeidelbergInventors: Michael Hundemer, Olaf Christensen
-
Publication number: 20150093366Abstract: The object of the present invention is to provide a cell that can exhibit physiological activity based on galectin-9, a method for producing the cell, and use of the cell. In order to achieve the above object, the cell of the present invention contains galectin-9, and the galectin-9 is expressed on a cell surface.Type: ApplicationFiled: September 29, 2014Publication date: April 2, 2015Inventors: Mitsuomi HIRASHIMA, Toshiro NIKI, Tomohiro ARIKAWA, Souichi OOMIZU, Takeshi KADOWAKI
-
Patent number: 8992907Abstract: Compositions comprising human Tr1 cells directed to a food antigen from common human diet and methods for treating an intestinal inflammatory condition.Type: GrantFiled: November 26, 2008Date of Patent: March 31, 2015Assignee: TxcellInventor: Arnaud Foussat
-
Publication number: 20150086520Abstract: The present invention provides cell compositions and methods of using treating disorders, such as inflammatory disorders, such as atherosclerosis and cardiovascular disease.Type: ApplicationFiled: March 14, 2013Publication date: March 26, 2015Inventors: Kelly Ledford, Ronna L. Bartel, Frank Zeigler
-
Patent number: 8986679Abstract: A method of treating a cellular proliferative disorder in a subject by obtaining from a subject a bodily fluid sample containing a plurality of cells, incubating the sample with EDTA or heparin in a container until the sample is separated into an upper layer and a lower layer, collecting the upper layer, isolating from the upper layer a population of somatic stem cells that are 0.3-6.0 micrometers in size, differentiating the somatic stem cells to dendritic cells in a medium containing GCSF, SCF, EGF, PDGF, bFGF, and IL-3, purifying the dendritic cells, contacting the dendritic cells thus purified with a cancer antigen, and administrating an effective amount of the dendritic cells presenting the cancer antigen to a subject in need thereof.Type: GrantFiled: May 16, 2013Date of Patent: March 24, 2015Assignee: Stembios Technologies, Inc.Inventor: James Wang
-
Publication number: 20150079053Abstract: Isolated pluralities of T cells which recognize at least one epitope of a mucosally restricted antigen and pharmaceutical compositions comprising the same are disclosed. Methods of making a plurality of T cells that recognize at least one epitope of a mucosally restricted antigen are also disclosed. Methods of treating an individual who has been diagnosed with cancer of a mucosal tissue or preventing such cancer in an individual at elevated risk are disclosed as are nucleic acid molecules that comprise a nucleotide sequence that encode proteins that recognize at least one epitope of a mucosally restricted antigen and T cells comprising such nucleic acid molecules.Type: ApplicationFiled: November 20, 2014Publication date: March 19, 2015Inventors: Scott A. Waldman, Adam E. Snook
-
Publication number: 20150079032Abstract: The invention relates to therapy and methods of applying the therapy to a patient. The invention includes the introduction of immature dendritic cells into the patient and the introduction of anti-TNF antibody into the patient. The immature dendritic cells are introduced intratumorally and/or through vessel and the anti-TNF antibody is introduced intratumorally and/or through vessel and/or subcutaneously. The immature dendritic cells can be formed by collecting monocyte cells from the patient and culturing the cells in a culture medium. The invention can be effective to regress, reduce or eliminate tumor cells in tumor tissue of the patients, including metastasized tumors. Further, the treatment of the invention is effective in the absence of conventional therapy, such as radiotherapy and chemotherapy.Type: ApplicationFiled: November 21, 2014Publication date: March 19, 2015Applicant: HASUMI INTERNATIONAL RESEARCH FOUNDATIONInventor: KENICHIRO HASUMI
-
Publication number: 20150071892Abstract: Methods of making activated immunostimulatory cell compositions, activated immunostimulatory cell compositions, and methods of using those compositions to stimulate therapeutic immune response to infectious organisms are described.Type: ApplicationFiled: March 13, 2013Publication date: March 12, 2015Inventors: Irene Ginis, Alan Smith, Marina Bubis, Mitchell Shirvan
-
Publication number: 20150064154Abstract: Methods and compositions related to the use of a protein with kynureninase activity are described. For example, in certain aspects there may be disclosed a modified kynureninase capable of degrading kynurenine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with kynurenine depletion using the disclosed proteins or nucleic acids.Type: ApplicationFiled: August 29, 2014Publication date: March 5, 2015Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: George GEORGIOU, Everett STONE
-
Publication number: 20150064153Abstract: Described herein is a novel, highly efficient system to remove erythrocytes and purify leukocytes would raise the quality of UCB and other transplant grafts, thereby significantly improving patient outcomes.Type: ApplicationFiled: March 14, 2014Publication date: March 5, 2015Applicants: THE TRUSTEES OF PRINCETON UNIVERSITY, UNIVERSITY OF MARYLAND, BALTIMOREInventors: Curt I. Civin, James C. Sturm, Robert H. Austin
-
Publication number: 20150056252Abstract: The present invention includes compositions and methods for the diagnosis and treatment of lung cancer with a recombinant tumor-associated antigen loaded antigen presenting cell that generates a cytotoxic T lymphocyte specific immune response to at least one of SP17, AKAP-4, or PTTG1 expressed by one or more lung cancer cells.Type: ApplicationFiled: February 12, 2014Publication date: February 26, 2015Applicant: Texas Tech University SystemInventor: Maurizio Chiriva-Internati
-
Patent number: 8961957Abstract: The invention relates to therapy and methods of applying the therapy to cancer patients. The invention includes introducing intratumorally cytotoxic T lymphocyte and/or NKT cells, and prior to, coincident with, or following introducing intratumorally the cytotoxic T lymphocyte and/or NKT cells, introducing intratumorally anti-TNF and/or anti-IL-10 to the patient. The cytotoxic T lymphocyte and/or NKT cells can be induced by the intratumoral introduction of immature dendritic cells to the patient. This therapy of the invention can be effective to regress, reduce or eliminate tumor cells in tumor tissue of the patients in the absence of radiation therapy.Type: GrantFiled: June 27, 2013Date of Patent: February 24, 2015Assignee: Hasumi International Research FoundationInventor: Kenichiro Hasumi
-
Publication number: 20150037304Abstract: Disclosed herein are methods and compositions for modulating the expression of a HLA locus, including cells that lack expression of one or more classic HLA genes but are not targeted by Natural Killer (NK) cells for lysis.Type: ApplicationFiled: March 12, 2014Publication date: February 5, 2015Inventors: Philip D. Gregory, Laurence J.N. Cooper, Hiroki Torikai
-
Publication number: 20150037303Abstract: The invention discloses novel methods, compositions of matter, and kits for the treatment of disorders affecting the hematopoietic system. Patients are administered an autologous cellular mixture derived from adipose stromal vascular fraction, said cellular mixture comprising endothelial cells, endothelial progenitor cells, T regulatory cells, monocytes, and hematopoietic stem cells. In one embodiment, treatment is provided for patients suffering from inflammatory disorders including aplastic anemia.Type: ApplicationFiled: August 1, 2013Publication date: February 5, 2015Applicant: Regen BioPharma, IncInventors: Thomas Ichim, David Koos
-
Publication number: 20150037355Abstract: The present invention relates to methods and compositions for use in inducing tumor-specific antibody mediated complement-dependent cytotoxic response in an animal having a tumor comprising administering to said animal a composition comprising a replication competent oncolytic virus wherein administration of the composition induces in the animal production of antibodies that mediate a CDC response specific to said tumor.Type: ApplicationFiled: January 4, 2012Publication date: February 5, 2015Applicants: SILLAJEN, INC., JENNEREX INC.Inventors: David Kirn, John Bell, Caroline Breitback, Anne Moon, Tae-Ho Hwang, Yu Kyoung Lee, Mi-kyung Kim
-
Publication number: 20150030635Abstract: Methods of making activated immunostimulatory cell compositions, activated immunostimulatory cell compositions, and methods of using those compositions to stimulate therapeutic immune responses to tumors are described.Type: ApplicationFiled: March 13, 2013Publication date: January 29, 2015Inventors: Irene Ginis, Alan Smith, Adi Zuloff-Shani, Marina Bubis, Mitchell Shirvan
-
Publication number: 20150023938Abstract: Methods for preparing ex vivo T cell cultures using IL-21 compositions for use in adoptive immunotherapy are described. Addition of IL-21 to cultures of non-terminally differentiated T cells population, either isolated or present in peripheral blood mononuclear cells are exposed to one or more tumor antigens, and in the presence of IL-21 compositions and antigen presenting cells (APCs), the resulting T cell population has an enhanced antigen-specificity, and can be reintroduced into the patient. Methods are also disclosed for identifying tumor antigens by culturing T cell populations exposed to IL-21 compositions and APCs in the presence of tumor material.Type: ApplicationFiled: August 25, 2014Publication date: January 22, 2015Applicant: FRED HUTCHINSON CANCER RESEARCH CENTERInventor: Cassian Yee
-
Publication number: 20150023939Abstract: An apparatus that allows for separating and collecting a fraction of a sample. The apparatus, when used with a centrifuge, allows for the creation of at least three fractions in the apparatus. It also provides for a new method of extracting the buffy coat phase from a whole blood sample. A buoy system that may include a first buoy portion and a second buoy member operably interconnected may be used to form at least three fractions from a sample during a substantially single centrifugation process. Therefore, the separation of various fractions may be substantially quick and efficient.Type: ApplicationFiled: October 9, 2014Publication date: January 22, 2015Inventor: Jennifer E. WOODELL-MAY
-
Publication number: 20150023937Abstract: Embodiments of the invention employ methods and compositions for enhancing potency of immune cells that express one or more therapeutic proteins. In certain cases, the methods modulate expression of a CAR transgene in an immune cell, such as a T cell. Specific embodiments employ the exposure of cells and/or individuals to be treated with the cells with an effective amount of at least one agent that upregulates expression of the therapeutic protein, such as a mitogen, histone deacetylase inhibitor, and or DNA methyltransferase inhibitor.Type: ApplicationFiled: July 18, 2014Publication date: January 22, 2015Inventors: Juan Fernando Vera Valdes, Malcolm Brenner, Usanarat Anurathapan
-
Publication number: 20150023919Abstract: The present disclosure relates to methods of inducing tolerance to lung allograft transplantation. These methods comprise increasing nitric oxide, increasing suppressor CD8+ T cells and/or suppressing deleterious CD8+ and CD4+ T cells.Type: ApplicationFiled: July 17, 2014Publication date: January 22, 2015Inventors: Alexander Sasha Krupnick, Daniel Kreisel, Andrew Gelman
-
Patent number: 8932806Abstract: The invention relates to a method for identifying T-cell stimulating protein fragments using the following steps: a) detecting the amino acid sequence of an antigen; b) subdividing the found amino acid sequence of the antigen into protein fragments; c) synthesizing at least one protein fragment; d) incubating a suspension containing t-cells with the protein fragments; e) identifying an induced T-cell cytokine or activation marker by flow-through cytometry, and; f) assigning the T-cells, with which T-cell cytokines and/or activation markers were identified, to the protein fragments which were incubated with the T-cells. The corresponding protein fragments/peptides are synthetically produced with the assistance of the detected positive sequence, and said corresponding protein fragments/peptides can be utilized to produce a medicament for immunostimulation.Type: GrantFiled: January 15, 1999Date of Patent: January 13, 2015Inventors: Florian Kern, Hans-Dieter Volk, Peter Walden, Alexander Scheffold, Rainer Blasczyk
-
Publication number: 20150010517Abstract: An apparatus for the preparation of cells for implantation into a living body is disclosed. The apparatus comprises a vessel substantially impermeable to gaseous oxygen; and fluid within said vessel, the fluid having a maximal dissolved oxygen capacity substantially equivalent to normal saline yet having a hypoxic oxygen concentration between about 0% to about 5% of said maximal dissolved oxygen capacity. The bag oxygen concentration level remains low when the apparatus is stored at 22°-25° C. in normal atmospheric conditions for a period of at least 30 days. The present invention simplifies the process of achieving donor cell hypoxic preconditioning for cell implantation, and may be used to bathe said cells to be transplanted for a sufficient time to activate the hypoxic metabolic pathway.Type: ApplicationFiled: September 22, 2014Publication date: January 8, 2015Inventor: John R. Chapman
-
Publication number: 20150010519Abstract: The present invention concerns methods of generating CTLs that are able to target at least one antigen from two or more viruses. The method includes exposing mixtures of peptides for different antigens to the same plurality of PBMCs and, at least in certain aspects, expanding the cells in the presence of IL4 and IL7.Type: ApplicationFiled: February 8, 2013Publication date: January 8, 2015Inventors: Ann Marie Leen, Juan Fernando Vera Valdes, Cliona M. Rooney, Ulrike Gerdemann
-
Patent number: 8926964Abstract: Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer or viral infection.Type: GrantFiled: July 13, 2011Date of Patent: January 6, 2015Assignee: Anthrogenesis CorporationInventors: Robert J. Hariri, Mohammad A. Heidaran, Stephen Jasko, Lin Kang, Eric Law, Ajai Pal, Bhavani Stout, Vanessa Voskinarian-Berse, Andrew Zeitlin, Xiaokui Zhang
-
Publication number: 20150004176Abstract: The present specification discloses regulatory T cells, compositions including regulatory T cells, methods of identifying, isolating, enriching, obtaining, and/or expanding regulatory T cells or subset populations thereof, kits including components useful for performing such methods, and methods of treating an immune-based disorder in an individual by administering regulatory T cells or compositions comprising such regulatory T cells to an individual in need thereof.Type: ApplicationFiled: June 29, 2012Publication date: January 1, 2015Applicant: BECKMAN COULTER, INC.Inventor: Carlos A. Garcia Santana
-
Publication number: 20140377291Abstract: Provided herein are sphingolipid compounds that are useful for activating natural killer T cells. Also provided are methods for treating or preventing a disease or disorder that is treatable by activating the immune system by stimulating natural killer T cells. The compounds are therefore useful for treating or reducing the likelihood of occurrence of an immune diseases and disorders, such as autoimmune diseases or disorders. The compounds may also be used for treating or reducing the likelihood of occurrence of a microbial infection or for treating or reducing the likelihood of occurrence of a cancer in a subject by administering the sphingolipid compounds described herein.Type: ApplicationFiled: February 7, 2013Publication date: December 25, 2014Inventors: Michael A. Fischbach, Jeffrey A. Bluestone, Cristina Penaranda, Laura Brown, Jon Clardy
-
Publication number: 20140377240Abstract: Disclosed herein are methods and compositions for expanding T-regulatory cells (“Treg” cells), resulting in “conditioned Treg cells.” Also disclosed herein are methods and compositions useful for modulating an autoimmune reaction and for treating or ameliorating immune-related diseases, disorders and conditions using the conditioned Treg cells.Type: ApplicationFiled: January 17, 2013Publication date: December 25, 2014Applicant: Northeastern UniversityInventors: Michail Sitkovsky, Akio Ohta, Akiko Ohta
-
Patent number: 8916147Abstract: The present invention provides a method of treating a disease in a subject in need thereof via non-syngeneic graft administration without or with reduced concomitant graft rejection. The method comprises administering to the subject a therapeutically effective graft being non-syngeneic with the subject, and a dose of tolerogenic cells being non-syngeneic with both the subject and the graft for preventing or reducing graft rejection in the subject, thereby treating the disease in the subject.Type: GrantFiled: August 21, 2006Date of Patent: December 23, 2014Assignee: Yeda Research and Devolpment Co. Ltd.Inventor: Yair Reisner
-
Publication number: 20140369984Abstract: The present disclosure provides biomaterials and methods for preventing and minimizing progression of cartilage and/or connective tissue damage. Also provided herein are biomaterials and methods for alleviating and/or reducing the risk for developing arthritis (e.g., osteoarthritis) associated with joint injury and/or joint surgery.Type: ApplicationFiled: February 1, 2013Publication date: December 18, 2014Applicants: Children's Medical Center Corporation, Rhode Island HospitalInventors: Martha M. Murray, Braden C. Fleming
-
Publication number: 20140369955Abstract: Materials and methods for obtaining populations of lymphocytes and administering the population of lymphocytes to a subject are disclosed herein. In particular, disclosed herein are materials and methods for obtaining lymphocyte populations that contain at least about 0.5×109 NK cells per kilogram weight of the subject from which the cells are harvested.Type: ApplicationFiled: January 24, 2014Publication date: December 18, 2014Applicant: Mayo Foundation for Medical Education and ResearchInventors: Svetomir N. Markovic, Luis F. Porrata
-
Publication number: 20140369983Abstract: The present invention is directed to compositions and methods for treatment of ischemic diseases and conditions, particularly myocardial, CNS/brain and limb ischemia. More particularly, the present invention provides methods of treating disorders by administering monocytes obtained from blood, including umbilical cord blood, peripheral blood, or bone marrow to an individual in need of treatment, wherein the drug is administered to the individual at a time point specifically determined to provide therapeutic efficacy. In one embodiment, the cells are for injection into ischemic myocardium for the treatment of angina.Type: ApplicationFiled: July 21, 2014Publication date: December 18, 2014Applicant: UNIVERSITY OF SOUTH FLORIDAInventors: Paul R. Sanberg, Alison E. Willing
-
Patent number: 8911739Abstract: A method is provided for preventing rejection by an immune system of a recipient subject of a tissue transplanted from a donor subject into the recipient subject without the need for long-term administration of non-specific immunosuppressive drugs.Type: GrantFiled: February 9, 2010Date of Patent: December 16, 2014Assignees: Trustees of Columbia University in the City of New York, The National Institutes of Health (NIH)Inventors: Hong Jiang, Leonard Chess
-
Publication number: 20140363495Abstract: The invention provides peptides comprising a human cytolytic T lymphocyte (CTL) epitope from the human tumor-associated antigen (TAA) mucin 1 (MUC1) and analogs thereof, which can be used in vaccine prevention or therapy of cancer, as well as a nucleic acid encoding the peptide, a vector comprising the nucleic acid, a cell comprising the peptide, nucleic acid, or vector, and compositions thereof.Type: ApplicationFiled: January 3, 2013Publication date: December 11, 2014Inventors: Jeffrey Schlom, Kwong-Yok Tsang
-
Publication number: 20140363411Abstract: A subpopulation of peripheral blood mononuclear cells (PBMCs) that is substantially devoid of CD3+ cells, CD19+ cells, CD56+ cells and optionally of CD16+ cells, for use in treatment of CNS injury is provided.Type: ApplicationFiled: June 12, 2014Publication date: December 11, 2014Inventors: Michal Eisenbach-Schwartz, Ester Yoles, Ravid Schechter, Omer Miller
-
Publication number: 20140356321Abstract: Granulin-epithelin precursor (GEP), a pluripotent growth factor, is a hepatic oncofetal protein defining a cancer stem cell (CSC) population in liver cancer. The present invention provides the use of GEP inhibitors (including anti-GEP antibody) for inhibiting immune evasion by liver cancer cells and for eliminating liver cancer stem cells.Type: ApplicationFiled: May 30, 2014Publication date: December 4, 2014Applicant: THE UNIVERSITY OF HONG KONGInventors: Siu Tim Cheung, Sheung-Tat Fan, Phyllis Fung Yi Cheung
-
Publication number: 20140356339Abstract: The invention is directed to methods of measuring an immune response by comparing sequence-based clonotype frequency data from successively measured clonotype profiles. In particular, the invention includes immunotherapies of cancers, such as lymphomas, that include sensitive pre- and post-vaccination sequence-based measurements of changes in a patient's immune repertoire, thereby providing a sensitive measure of the likelihood of treatment success.Type: ApplicationFiled: August 31, 2012Publication date: December 4, 2014Applicant: SEQUENTA INC.Inventors: Malek Faham, Martin Moorehead, Thomas Willis
-
Publication number: 20140356318Abstract: The present invention comprises a method of treatment of an autoimmune disease involving a specific tolerance induction (“STI”) event, wherein the method includes: collecting a first sample from the patient prior to the STI event; detecting an STI event or performing a procedure that correlates in time to an STI event; collecting a second sample from the patient after the STI event; preparing lymphocytes from the first and second samples; preparing and sequencing DNA or cDNA from the prepared lymphocytes; identifying sequences of prevalent T or B cell receptors (“prevalent receptor sequences”) among the lymphocytes of the second sample; selecting a regulatory lymphocyte that carries at least one prevalent receptor sequence, which selected regulatory lymphocyte (i) expresses at least one prevalent receptor sequence or (ii) is generated from an autologous or allogeneic naïve lymphocyte, which naïve lymphocyte is engineered and induced to become a regulatory lymphocyte that expresses at least one prevalent recepType: ApplicationFiled: May 28, 2013Publication date: December 4, 2014Inventor: Israel Barken
-
Publication number: 20140348809Abstract: Compositions and methods are provided for generating T cells having a regulatory phenotype from conventional T (Tconv) cells. Such compositions and methods include culturing isolated, naïve Tconv cells with an effective amount of interleukin-35 (IL-35) until the cells have the regulatory phenotype. Also provided are methods to treat subject having or susceptible to having various disorders including, for example, immune system disorders with the T cells having the regulatory phenotype.Type: ApplicationFiled: August 8, 2014Publication date: November 27, 2014Inventors: Dario AA. Vignali, Lauren W. Collison
-
Publication number: 20140348902Abstract: Provided are TCL1 peptides that bind to MHC I (HLA-A2) on tumor cells or other antigen-presenting cells and are recognized by T-cell receptors on T cells. The TCL1 peptides may be therapeutically used to treat a cancer, such as a B cell malignancy, leukemia, or lymphoma. Methods for expanding a population of T cells that target TCL1 are also provided.Type: ApplicationFiled: November 19, 2012Publication date: November 27, 2014Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Sattva S. Neelapu, Jinsheng Weng
-
Publication number: 20140351961Abstract: Disclosed are methods and compositions for treating cancer that involved an isolated double stranded ribonucleic acid (dsRNA) molecule that inhibits the expression of Hsp-27.Type: ApplicationFiled: August 30, 2012Publication date: November 27, 2014Inventor: Alexzander A. Asea
-
Publication number: 20140348808Abstract: The present invention relates to immunomodulatory cells, methods for providing immunomodulatory cells, and therapeutic uses of the cells for the immune modulation of mammals in need thereof.Type: ApplicationFiled: May 18, 2012Publication date: November 27, 2014Inventor: Olga De La Rosa
-
Publication number: 20140341809Abstract: High-affinity variants of the DMF5 TCR, and methods of use thereof for the treatment and imaging of cancer in a patient.Type: ApplicationFiled: May 16, 2014Publication date: November 20, 2014Applicants: University of Massachusetts, University of Notre DameInventors: Brian G. Pierce, Zhiping Weng, Brian M. Baker
-
Patent number: 8889124Abstract: Tolerogenic populations of dendritic cells are provided, where the dendritic cells are characterized by expression of select tissue-specific homing receptors including the chemokine receptors CCR9; or CMKLR1; or the integrin CD103. The dendritic cells may be conventional/myeloid or plasmacytoid dendritic cells. The cells may be isolated from lymphoid tissue, from blood, or from in vitro culture, e.g. bone marrow culture, etc. Methods are provided for their identification, isolation and targeting in immunotherapeutic interventions in suppressing inflammatory disorders including autoimmunity, transplantation responses and allergic diseases. In some embodiments dendritic cell populations are fixed to render them immunosuppressive, thus allowing the cells to be typed and banked for future use.Type: GrantFiled: September 24, 2009Date of Patent: November 18, 2014Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Husein Hadeiba, Eugene C. Butcher
-
Publication number: 20140335046Abstract: A method of inducing or promoting hair growth on the scalp of a subject, comprising the steps of (i) providing an ECM composition including at least one ECM material, (ii) administering inciting event means to a target skin location on the subject to induce an inciting event, and (iii) administering a therapeutically effective amount of said ECM composition to the target skin location. In some embodiments, the ECM composition includes at least one additional biologically active agent.Type: ApplicationFiled: September 19, 2013Publication date: November 13, 2014Inventor: Robert G. Matheny